[صفحه اصلی ]     [ English ]  
:: صفحه اصلي :: درباره نشريه :: آخرين شماره :: تمام شماره‌ها :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
بخش‌های اصلی
صفحه اصلی::
اطلاعات نشریه::
آرشیو مجله و مقالات::
برای نویسندگان::
برای داوران::
ثبت نام و اشتراک::
کار آزمایی بالینی::
تماس با ما::
تسهیلات پایگاه::
::
هزینه چاپ مقاله در کومش
  • با توجه به تصمیمات گرفته شده مقالاتی که  به مجله کومش ارسال میشود، در صورت پذیرفته شدن برای چاپ، نویسنده مسئول باید مبلغ ۲۰۰۰۰۰۰ریال (۲۰۰ هزار تومان) جهت دریافت نامه پذیرش به حساب درآمد های دانشگاه واریز نمایند تا گواهی پذیرش مقاله صادر و مراحل بعدی انتشار مقاله انجام شود.
  • تبصره: این مصوبه شامل مقالات ارسالی همکاران دانشگاه علوم پزشکی سمنان نمی شود.
..
جستجو در پایگاه

جستجوی پیشرفته
..
دریافت اطلاعات پایگاه
نشانی پست الکترونیک خود را برای دریافت اطلاعات و اخبار پایگاه، در کادر زیر وارد کنید.
..
SCImago Metric

SCImago Journal & Country Rank

..
Google Scholar Metrics

Citation Indices from GS

Citation indicesAllSince 2012
Citations12501124
h-index1716
i10-index3932

..
:: چک لیست گزارش کار آزمایی بالینی ::
 | تاریخ ارسال: ۱۳۹۱/۱۲/۲ | 

 CONSORT Statement 2001 Checklist

  Items to include when reporting a randomized trial

 

  PAPER SECTION
And topic

Item

  Descriptor

  Reported on

  Page # 

TITLE & ABSTRACT

  1

  How participants were allocated to interventions (e.g., "random allocation", "randomized", or "randomly assigned").

 

  INTRODUCTION
Background

  2

  Scientific background and explanation of rationale .

 

  METHODS
Participants

  3

  Eligibility criteria for participants and the settings and locations where the data were collected .

 

  Interventions

  4

  Precise details of the interventions intended for each group and how and when they were actually administered .

 

  Objectives

  5

  Specific objectives and hypotheses .

 

  Outcomes

  6

  Clearly defined primary and secondary outcome measures and, when applicable, any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors).

 

  Sample size

  7

  How sample size was determined and, when applicable, explanation of any interim analyses and stopping rules .

 

  Randomization --
Sequence generation

  8

  Method used to generate the random allocation sequence, including details of any restrictions (e.g., blocking, stratification)

 

  Randomization --
Allocation concealment

  9

  Method used to implement the random allocation sequence (e.g., numbered containers or central telephone), clarifying whether the sequence was concealed until interventions were assigned.

 

  Randomization --
Implementation

  10

  Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups .

 

  Blinding (masking)

  11

  Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment . If done, how the success of blinding was evaluated .

 

  Statistical methods

  12

  Statistical methods used to compare groups for primary outcome(s) ; Methods for additional analyses , such as subgroup analyses and adjusted analyses.

 

RESULTS

  Participant flow

 

  13

  Flow of participants through each stage (a diagram is strongly recommended). Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the study protocol, and analyzed for the primary outcome. Describe protocol deviations from study as planned, together with reasons .

 

  Recruitment

  14

  Dates defining the periods of recruitment and follow-up .

 

  Baseline data

  15

  Baseline demographic and clinical characteristics of each group .

 

  Numbers analyzed

  16

  Number of participants (denominator) in each group included in each analysis and whether the analysis was by "intention-to-treat" . State the results in absolute numbers when feasible (e.g., 10/20, not 50%).

 

  Outcomes and estimation

  17

  For each primary and secondary outcome, a summary of results for each group, and the estimated effect size and its precision (e.g., 95% confidence interval).

 

  Ancillary analyses

  18

  Address multiplicity by reporting any other analyses performed , including subgroup analyses and adjusted analyses, indicating those pre-specified and those exploratory.

 

  Adverse events

  19

  All important adverse events or side effects in each intervention group .

 

  DISCUSSION
Interpretation

  20

  Interpretation of the results , taking into account study hypotheses, sources of potential bias or imprecision and the dangers associated with multiplicity of analyses and outcomes.

 

  Generalizability

  21

  Generalizability (external validity) of the trial findings .

 

  Overall evidence

  22

  General interpretation of the results in the context of current evidence .

 

  

  From Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357(9263):1191-1194.

  

  The CONSORT Statement 2001 checklist is intended to be accompanied with the explanatory document that facilitates its use. For more information, visit www.consort-statement.org.

دفعات مشاهده: 6752 بار   |   دفعات چاپ: 291 بار   |   دفعات ارسال به دیگران: 79 بار   |   0 نظر
::
برای مشاهده کل مطالب بخش چک لیست گزارش یک کار آمایی بالینی اینجا را کلیک کنید.
کومش Koomesh
Persian site map - English site map - Created in 0.044 seconds with 903 queries by yektaweb 3320